CDMOs (Contract Development Manufacturing
Organizations) are specialized companies that
offer services to pharmaceutical and biotech firms
to help them develop and manufacture
drugs. These organizations allow companies to
outsource complex production and development
processes, which can save time and reduce costs.
In recent years, China has emerged as a global hub
for CDMOs. Chinese CDMOs have become key
players in the pharmaceutical supply chain,
offering services like drug development, clinical
trials, and large-scale manufacturing.
Recently, the United States launched the US Bio
Secure Act which prohibits any US pharmaceutical
company from engaging in partnerships with
Chinese CDMOs. The act received bipartisan
support and was implemented in January 2024.